Simcere Pharmaceutical Receives First Generic Biapenem Certificate
This article was originally published in PharmAsia News
Simcere Pharmaceutical Group's first generic biapenem drug has received new drug certificate and production approval from China's State FDA. A newly launched generic drug enjoys a four-year assessment grace period during which SFDA declines applications of similar chemical compounds or drug administration routes whose R&D has not entered into clinical stages. Biapenem, like Merck's Tienam and Dainippon Sumitomo's Mepem, comes under carbapenem antibiotics. The drugs have a 1.6 billion yuan market in China, with 30 percent annual growth over the past three years. Simcere believes that the biapenem's approval will enhance the firm's long-term strategy of focusing on first-to-market anti-infection generic drugs. (Click here for more - Chinese Language)
You may also be interested in...
With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. The first of a two-part series on mental health focuses on transcranial magnetic stimulation systems. See what Neuronetics’ CEO Stephen Furlong said about it here.
US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.
Mallinckrodt's drug to treat hepatorenal syndrome met its primary endpoint of HRS reversal but FDA wants reassurance that this surrogate endpoint translates into a treatment effect on clinical outcomes. A greater incidence of respiratory failure in those receiving terlipressin "remains a significant safety concern," the agency says.